VERA as reported
- Net Income
- −$402M
Net Income · +84% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$339M
Free Cash Flow · +82% year on year · trailing twelve months to Q2 2026
- EPS
- −$5.86
EPS · +64% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$402M | +84% | Q2 2026 |
| EPS | −$5.86 | +64% | Q2 2026 |
| ROE | −71% | n/a | Q2 2026 |
| ROA | −56% | n/a | Q2 2026 |
| ROIC | 1252% | n/a | Q2 2026 |
| Free Cash Flow | −$339M | +82% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Vera Therapeutics, Inc. (VERA) - Net IncomeNet IncomeVera Therapeutics, Inc. (VERA)